OKYO OKYO Pharma

OKYO Pharma Limited ("OKYO" or the "Company") - Company Presentation

OKYO Pharma Limited ("OKYO" or the "Company") - Company Presentation

LONDON, Aug. 03, 2020 (GLOBE NEWSWIRE) -- OKYO, the life sciences and biotechnology company, focused on the discovery and development of novel molecules to treat inflammatory dry eye diseases and chronic pain, is pleased to announce that, further to the announcement made on Friday 31 July, the investor webinar, hosted by RedChip Companies, on Sunday, August 2, 2020 can be viewed at .

About OKYO

OKYO Pharma Limited (LSE: OKYO) is a life sciences and biotechnology company admitted to listing on the standard segment of the Official List of the UK Financial Conduct Authority and to trading on the Main Market for listed securities of the London Stock Exchange plc. OKYO is focusing on the discovery and development of novel molecules to treat inflammatory dry eye diseases and chronic pain.

Enquiries:

OKYO Pharma LimitedWilly Simon+44 (0)20 7495 2379
Optiva Securities Limited



 		Robert Emmet+ 44 (0)20 3981 4173

For further information, please visit the Company's website at

EN
03/08/2020

Underlying

OKYOOKYO Pharma

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on OKYO Pharma

 PRESS RELEASE
Free
OKYO OKYO PHARMA

OKYO Pharma to Present at the GPCRs-Targeted Drug Discovery Summit

OKYO Pharma to Present at the GPCRs-Targeted Drug Discovery Summit LONDON and NEW YORK, May 19, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain, a severe ocular condition without an FDA approved therapy, and for inflammatory eye diseases, announced that its CEO, Gary S. Jacob, Ph.D., will be giving an oral presentation at the 4th Annual GPCRs-Targeted Drug Discovery Summit in Boston, MA on May 22, 2025. Dr. Jacob’s presentation will cover the development of...

May 19, 2025 1 EN
 PRESS RELEASE
Free
OKYO OKYO PHARMA

FDA Grants OKYO Pharma Fast Track Designation to Urcosimod for Neuropa...

FDA Grants OKYO Pharma Fast Track Designation to Urcosimod for Neuropathic Corneal Pain LONDON and NEW YORK, May 01, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing urcosimod (formerly called OK-101) to treat NCP, an ocular condition associated with chronic and often severe pain but without an FDA-approved therapy, announces that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to urcosimod for the treatment of neuropathic corneal pain (NCP). Fast Track designation by the ...

May 1, 2025 1 EN
 PRESS RELEASE
Free
OKYO OKYO PHARMA

OKYO Pharma Announces Plans to Accelerate the Clinical Development of ...

OKYO Pharma Announces Plans to Accelerate the Clinical Development of Urcosimod to Treat Neuropathic Corneal Pain Urcosimod phase 2 trial treating Neuropathic Corneal Pain (“NCP”) patients was initiated in October 2024 and designed as a double-masked, randomized, 12-week placebo-controlled trial.OKYO Pharma plans to analyze the efficacy data from the 17 patients who have now completed the Phase 2 trial.OKYO Pharma plans for a meeting with FDA following evaluation of clinical data. LONDON and NEW YORK, April 30, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), an ophthalmology...

April 30, 2025 1 EN
 PRESS RELEASE
Free
OKYO OKYO PHARMA

OKYO Pharma Announces Positive Data in Long-Term Stability of Urcosimo...

OKYO Pharma Announces Positive Data in Long-Term Stability of Urcosimod Urcosimod in Phase 2 clinical trial for Neuropathic Corneal Pain shown to have Long-Term StabilityUrcosimod stable in single-use ampoules for more than 2½ yearsFDA requires drug to show long-term shelf stability for approvalDaily administration to patients via ampoules can minimize risk of contamination LONDON and NEW YORK, March 31, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: ), a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain (NCP), a...

March 31, 2025 1 EN
 PRESS RELEASE
Free
OKYO OKYO PHARMA

OKYO Pharma Files for Fast Track Designation with FDA for Urcosimod to...

OKYO Pharma Files for Fast Track Designation with FDA for Urcosimod to Treat Neuropathic Corneal Pain LONDON and NEW YORK, March 10, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: ), a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain, a severe ocular condition without an FDA approved therapy, and for inflammatory dry eye disease, a multi-billion-dollar market, is pleased to announce the filing of its application for Fast Track designation with the U.S. Food and Drug Administration (FDA) for urcosimod (formerly kn...

March 10, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch